The green light in the US is the first worldwide for Enflonsia (clesrovimab) and makes the long-acting antibody the first competitor to Sanofi and AstraZeneca's blockbuster Beyfortus (nirsevimab ...

MSD's Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

In this week’s edition of InnovationRx, we look at RFK Jr.’s vaccine advisory committee purge, a tech billionaire’s funding ...

Sanofi is speeding up shipping its respiratory syncytial virus (RSV) preventative antibody Beyfortus to get ahead of what it believes will be strong demand in the 2025–26 season. Distribution of ...

MSD's Enflonsia (clesrovimab) has received FDA approval for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or ...

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

Clesrovimab joins the monoclonal antibody nirsevimab (Beyfortus), as well as the maternal bivalent RSV prefusion F protein vaccine (Abrysvo), in the growing arsenal of options to protect against ...